Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Epidemiologically inferred reverse zoonosis and intra-household zoonotic re-exposure of <i>Mycobacterium tuberculosis</i> in a domestic dog: a one health alert and the diagnostic potential of hypercalcaemia.

Frontiers in veterinary science·2026
Same author

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.

Nature communications·2026
Same author

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.

Pathogens & immunity·2026
Same author

Diagnostic accuracy study of the multiplex Truenat MTB Ultima/COVID-19 assay for simultaneous detection of Tuberculosis and SARS-CoV2 (COVID-19).

PLOS global public health·2026
Same author

TBSure: an ESGMYC survey of pediatric TB management practices in high-income countries.

Frontiers in public health·2026
Same author

Genomic characterization of the emerging multidrug-resistant <i>Klebsiella pneumoniae</i> ST6668 clone in northern Italy, 2020-2025.

Microbiology spectrum·2026
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
Same journal

Community-based tuberculosis screening with computer-aided detection technology alone and in combination with point-of-care C-reactive protein testing: a paired screen-positive trial.

The Lancet. Infectious diseases·2026
Same journal

Context matters: WHO-recommended tools in combinations validated for community tuberculosis screening.

The Lancet. Infectious diseases·2026
Same journal

Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.

Francesca Saluzzo1, Seda Yerlikaya2, Susan Elizabeth Dorman3

  • 1Vita Salute San Raffaele University, Milan, Italy; IRCCS San Raffaele Scientific Institute, Department of Immunology, Transplantation and Infectious Diseases, Milan, Italy.

The Lancet. Infectious Diseases
|June 1, 2026
PubMed
Summary
This summary is machine-generated.

Emerging resistance to new tuberculosis drugs threatens treatment efficacy. Developing rapid drug susceptibility testing alongside new drug development is crucial for preserving novel tuberculosis therapies and improving patient care globally.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Area of Science:

  • Microbiology
  • Drug Development
  • Public Health

Background:

  • The emergence of resistance to novel tuberculosis (TB) drugs like bedaquiline poses a significant threat to the effectiveness of new treatment regimens.
  • The development of all-oral regimens for rifampicin-resistant and multidrug-resistant TB is jeopardized by rising drug resistance.
  • A critical barrier to combating TB drug resistance is the slow development of reliable diagnostic tools for novel compounds.

Purpose of the Study:

  • To propose a framework for integrating drug susceptibility testing (DST) development with TB drug development.
  • To address the urgent need for rapid resistance detection to safeguard novel TB treatments.
  • To accelerate the development and implementation of DST for new TB drugs.

Main Methods:

  • Outlining a framework for early-stage resistance profiling and defining epidemiological cutoff values.
  • Highlighting the necessity for structured partnerships among drug developers, diagnostic manufacturers, regulators, research institutions, funders, and policymakers.
  • Proposing a roadmap for collaborative platforms for data sharing, genomic analysis, and diagnostic innovation.

Main Results:

  • Identified key gaps in the current TB drug and diagnostic development pipeline.
  • Proposed a structured approach to align DST development with novel drug introduction.
  • Emphasized the need for multi-stakeholder collaboration to accelerate progress.

Conclusions:

  • Integrating DST development into the TB drug pipeline is essential to combat emerging resistance.
  • Collaborative efforts and innovation in diagnostics are critical to ensure resistance detection keeps pace with drug development.
  • This integrated approach will help preserve novel TB treatments and enhance global TB control efforts.